Blog

Breast Cancer

Jan 29, 2025, 22:27

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared on X:

“Phase 3 KEYNOTE756 trial –

1st interim analysis:

Pembro + chemo

pCR in high-risk early ER+/HER2− Breast Cancer (24.3% vs 15.6%)

Manageable safety

EFS data maturing. ”

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial | Nature Medicine

Authors: Fatima Cardoso, Joyce O’Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, Javier Cortes, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Peter A. Fasching, Zhimin Shao, Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez, Gábor Rubovszky, Laura Spring, Seock-Ah Im, Rina Hui, Toshimi Takano, Fabrice André, Hiroyuki Yasojima, Yu Ding, Liyi Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer

Aditya Bardia cancer David W. Cescon Delphine Loirat Fabrice Andre Fatima Cardoso Gábor Rubovszky Heather McArthur Hiroyuki Yasojima Javier Cortés Joyce O'Shaughnessy Konstantinos Tryfonidis Kristina Jankovic Laura Spring Liyi Jia Manuel Gonzalez Fernandez Melinda L. Telli Nadia Harbeck OncoDaily Oncology Peter A. Fasching Peter Schmid Rina Hui Seock-Ah Im Toshimi Takano Vassiliki Karantza Yeon Hee Park Yu Ding Zhenzhen Liu Zhimin Shao

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025